IMCI is a pharmaceutical company that develops innovative pharma-grade and formulated cannabis-based medications to treat chronic indications with a global reach. IMCI has developed a precise and effective dose together with an easy-to-use administration, suitable for any patient population at any time and place via its iCann medicinal cannabis platform. IMCI research and development is based on an Israeli leading academic research institution in collaboration with established Israeli pharmaceutical providers which together with its team members, possess a proven track record in developing innovative cannabis-based medications.